

# INDEX

Note: Page numbers followed by “*f*” indicate figures, and “*t*” indicate tables.

## A

Antibody-dependent enhancement of infectivity (ADEI), 270–271  
Antiviral selection, CoV enzymatic activities, 273  
inhibitors, vacuolar acidification, 273–274  
p38 MAPK, 274

## C

Cap-dependent translation, 170–171  
Cellular proteins, CoV replication  
BCoV, 150  
DDX5 and DDX1, 151  
hnRNP A1, 149–150  
PABP, 150  
TGEV, 149–150  
Circulating virulent-avirulent FCoV hypothesis, 203–204  
*cis*-acting RNA elements, CoV  
cellular proteins, role of  
BCoV, 150  
DDX5 and DDX1, 151  
hnRNP A1, 149–150  
PABP, 150  
TGEV, 149–150  
*Coronaviridae* classification, 128  
DI RNAs  
definition, 131–132  
identification and characterization, 132  
leader switching, 132  
genome replication and transcription  
3'-5' exoribonuclease, 129–130  
ORF, 131  
RdRp, 129–130  
Sg minus-strand RNAs, 130–131  
transcription-regulating sequences (TRSs), 130–131  
nsp, 128–129  
ORF1a and ORF1b, 128–129  
RNA elements and genome packaging, 148–149

subgenomic messenger RNAs (sg mRNAs), 128–129  
3'-terminal  
functional roles, 145–148  
structural features, 142–145  
5'-terminal  
functional roles, 136–141  
structural features, 133–136  
zoonotic coronaviruses, 128

Coronavirus (CoV)  
eIF2 $\alpha$  phosphorylation activation, 182–183  
ER stress and unfolded protein response, 180–181  
genome organization and gene expression strategy  
discontinuous extension, 170  
eIF4F and the 43S preinitiation complex, 169–170  
ORFs, 169  
subgenomic minus-strand RNAs, 170  
transcription regulatory sequences (TRS), 169

HCoV  
229E-infected cells, 170–171, 184  
ORF, 174–175  
SARS-CoV and MERS-CoV, 168  
 $m^6A$ -modification, 184  
MERS-CoV, 168  
MHV-infected cells, 184–185  
mRNA translation  
cap-dependent translation, 170–171  
IRES-mediated translation, 175–176  
leaky scanning translation mechanism, internal ORFs, 174–175  
N protein-mediated enhancement, 177–178  
poly(A) tail length changes, 172  
ribosomal frameshift, 172–173  
ribosomal shunting mechanism, 174  
structural features, 184  
upstream ORFs (uORF), 176

## Coronavirus (CoV) (*Continued*)

- viral enzymes, 171–172
- viral UTRs, 177
- PERK activation, 182–183
- PKR activation, 182–183
- protein suppressors, translation
  - 7a protein, 180
  - eIF3f, 180
  - elongation factor 1 alpha (eEF1 $\alpha$ ), 180
  - MERS-CoV nsp1, 179
  - SARS-CoV nsp1, 179
  - 40S ribosomal subunits, 178–179
- SARS-CoV, 168
- stress granules and processing bodies, 181–182
- structural proteins, 168–169
- translation mechanism, animal cells
  - cap-dependent translation initiation, 167–168
  - eukaryotic cells, 166–167
  - eukaryotic initiation factors (eIFs), 167
  - IRES, 167–168
- viral gene expression, 183–184
- CoV S protein. *See* Spike protein (S) and tropism changes, CoV
- Cross-species transmission, 31

## D

- Defective interfering RNAs (DI RNAs)
  - definition, 131–132
  - identification and characterization, 132
  - leader switching, 132
- Dendritic cells (DCs)
  - cytokines and chemokines, 273
  - immune cells, SARS-CoV and MERS-CoV, 271, 272*t*
  - MERS-CoV interaction, 272
  - SARS-CoV, 272–273
  - virus replication, 271–272

## E

- Envelope protein
  - SARS-CoV, 10
  - structural features, 10–11
  - VLP, 9–10
- Eosinophilia induction, 270–271
- Epithelial cells, 271

## F

- Feline coronaviruses (FCoVs)
  - accessory genes and proteins
    - ORF 3a, 196
    - ORF7a, 196–197
    - ORF 3b, 196
    - ORF7b, 196–197
    - ORF 3c, 196
    - S and E genes, 195–196
    - sgRNA3, 196
    - TGEV, 195–196
  - discriminatory mutations, 210
- FECV
  - seropositivity rates, 199
  - symptomless persistent infections, 199–200
  - transmission, 200
- FIPV
  - characteristic lesions, 200–201
  - clinical forms, 201–202
  - immunosuppression, 202
  - incidence of, 203
  - incubation time, 202
  - origin of, 203–204
- molecular pathogenesis, FECV *vs.* FIPV
  - 7a gene, 204
  - 7b gene, 204–205
  - 3c gene, 204
  - furin cleavage site, 206
  - heptad repeat 1 (HR1) region, 205–206
  - mutations, 205
- reverse genetics
  - bacterial artificial chromosome (BAC), 207–208
  - cDNA, 208–209
  - FCoV Black sequence, 209–210
  - recombinant viruses, 207
  - targeted RNA recombination, 206–207
- role of accessory proteins, 211
- serotypes and cellular receptor usage
  - feline aminopeptidase N (fAPN), 198–199
  - serotype I, 197–198
  - serotype II, 198–199
- S gene mutations, 210
- taxonomy and genome organization, 194–195, 195*f*

**Feline enteric coronavirus (FECV)**

*vs.* FIPV  
7a gene, 204  
7b gene, 204–205  
3c gene, 204  
furin cleavage site, 206  
heptad repeat 1 (HR1) region, 205–206  
mutations, 205  
seropositivity rates, 199  
symptomless persistent infections, 199–200  
transmission, 200

**Feline infectious peritonitis (FIP), 204–206.**

*See also* Feline infectious peritonitis virus (FIPV)

Feline infectious peritonitis virus (FIPV)  
characteristic lesions, 200–201  
clinical forms, 201–202  
*vs.* FECV  
7a gene, 204  
7b gene, 204–205  
3c gene, 204  
furin cleavage site, 206  
heptad repeat 1 (HR1) region, 205–206  
mutations, 205  
immunosuppression, 202  
incidence of, 203  
incubation time, 202  
origin of, 203–204

**G****Genome replication and transcription**

3'-5' exoribonuclease, 129–130  
ORF, 131  
RdRp, 129–130  
Sg minus-strand RNAs, 130–131  
transcription-regulating sequences (TRSSs), 130–131

Genomic packaging signal (PS)  
conservation and lineage, 148–149  
discovery, 148–149  
role of, 149  
TGEV, 149

**H**

Host gene expression, 178–179  
Host translational shutoff, 181–182

**Human CoV (HCoV)**

229E-infected cells, 170–171, 184  
IFN response  
human MxA, 227–228  
IFITMs, 227–228  
ISG, 228  
2'-5' oligoadenylate synthetase (OAS), 227–228  
ORF, 174–175  
SARS-CoV and MERS-CoV, 168

**I****IFN-gamma, 223**

IFN-induced transmembrane (IFITMs), 227–228

IFN-lambda 1–4, 223

Inactivated whole virus, 256

Innate immunity modulators, 261–263, 261f

**Interferon (IFN) response**

antiviral action, human CoV  
human MxA, 227–228  
IFITMs, 227–228  
IFN-stimulated genes (ISG), 228  
2'-5' oligoadenylate synthetase (OAS), 227–228

**CoV genome**

genome organization, 220–221, 221f  
life cycle, 221–222  
RTC, 221–222  
sgRNA, 221–222

**induction, inhibition of**

dsRNA, 228–229  
IRF3, 229–231

mechanisms and factors, 229–231, 230–231f

MHV-A59, 229

ORF4a and ORF4b protein, 231–232  
pDCs, 229

resistance, 233–234, 233f

signaling, inhibition of, 232–233, 232f

**type I**

induction of, 224–225  
stimulated gene expression, 225–226  
types and signaling pathways, 222–223

Internal mutation hypothesis, 203–204

Internal ribosome entry site

(IRES)-mediated translation, 175–176

**L**

Leaky scanning translation mechanism, internal ORFs, 174–175  
 Live-attenuated vaccines  
   engineer attenuated CoVs, 258  
   IFN sensitivity, 259–261  
   innate immunity modulators, 261–263, 261/  
   MERS-CoV genes, 267–269  
   SARS-CoV genes, 263–267  
   virulence of, 258–259

**M**

Macrophages (MØ)  
   cytokines and chemokines, 273  
   immune cells, SARS-CoV and  
     MERS-CoV, 271, 272/  
   MERS-CoV interaction, 272  
   SARS-CoV, 272–273  
   virus replication, 271–272  
 Membrane protein  
   appearance and characteristics, 7–8, 7/  
   endodomains, 6  
   MLONG–RNP interactions, 6  
   virus-like particles (VLP) assembly, 6–8  
 Middle East respiratory syndrome (MERS) CoV  
   animal model, 253  
   antigenic complexity, 250–251  
   antiviral interferon response  
     (see Interferon (IFN) response)  
   cryo-EM reconstruction, 2–4, 3/  
   DCs, interaction, 272–273  
   DPP4, 252  
   as drug target, 89–90  
   envelope protein, 10  
   E protein, 10–11  
   ExoN, 102–103  
   HCoV, 168  
   hDPP4, 253–254  
   HR1 mutation, 46–47  
   immune cells, 271, 272/  
   interactions, 151  
   live-attenuated vaccines, 263–269  
   M protein, 9–10  
   NiRAN, 79  
   N protein, 8

nsp1, 179  
 nsp7, 67–68, 68/  
 nsp8, 68–70  
 nsp9, 70–71  
 nsp10, 71–72  
 nsp12, 76–77  
 nsp13, 81–82, 82/  
 nsp14, 103–104  
 nsp15, 106–109  
 nsp16, 97–98, 100–101  
 origin, 30–31  
 p38 MAPK, 274  
 protein receptor preference, 39  
 proteolytic cleavage sites, 45–46  
 RBM, 37–38  
 S<sub>1</sub> CTR changes, 43–44  
 SL3, 133–135  
 spike protein, 12  
 survival time, 5  
 5'-terminal genome, 136–137  
 transmission, 252

Molecular pathogenesis, FIP, 204–206  
 mRNA translation, CoV  
   cap-dependent translation, 170–171  
   IRES-mediated translation, 175–176  
   leaky scanning translation mechanism,  
     internal ORFs, 174–175  
   N protein-mediated enhancement,  
     177–178  
   poly(A) tail length changes, 172  
   ribosomal frameshift, 172–173  
   ribosomal shunting mechanism, 174  
   structural features, 184  
   upstream ORFs (uORF), 176  
   viral enzymes, 171–172  
   viral UTRs, 177

**N**

Nidovirus RdRp-associated  
   nucleotidyltransferase (NiRAN)  
     domain, 78–80  
 Nonstructural protein (nsp) 7, 67–68, 68/  
 Nonstructural protein (nsp) 9, 70–71  
 Nonstructural protein (nsp)10, 71–72  
 Nonstructural protein (nsp) 10–13–14–16  
   cap structure, 91–92  
   interferon-stimulated genes (ISGs), 90–91  
   7-methylguanosine (<sup>m7</sup>G), 90

mRNA, 90–91  
nsp14 N7-methyl transferase, 94–97, 95–96<sup>f</sup>  
nsp16 2'-O-methyl transferase, 97–101, 99–100<sup>f</sup>  
nsp13 RNA 5' triphosphatase, 92–93  
RNA guanylyl transferase (GTase), 93

Nonstructural protein (nsp)12  
characterization, 72–73  
inhibitors, 77–78  
initiation mechanism, 74–77, 75<sup>f</sup>  
NiRAN domain, 78–80  
RdRp domain, 73–74  
virus-encoded RdRp, 72–73

Nonstructural protein (nsp)13  
drug target, 89–90  
functional characterization, nidovirus helicase, 86–89  
HEL1, 81–83, 82<sup>f</sup>  
helicase-associated ZBD, 83–84  
nidovirus helicase structural biology, 84–86  
superfamilies (SFs), 80–81

Nonstructural protein (nsp) 15  
conserved domain, 108  
hexameric form, 109  
hexamerization, 109  
His residues, 110–111  
interrelated by topological permutation, 109  
Mn<sup>2+</sup> ions, 107–108  
nidovirus endoU domains, 106–107, 107<sup>f</sup>  
recombinant forms, 107–108  
RNase A, 110  
XendoU, *Xenopus laevis*, 106–107, 107<sup>f</sup>

Nonstructural protein (nsp) 8 and nsp7–nsp8 complexes, 68–70

Nonstructural protein (nsp) 14 ExoN  
DEDD exonucleases, 102  
genome size and ExoN conservation, 102–103  
metal ion-coordinating residues, 105–106  
Mg<sup>2+</sup> or Mn<sup>2+</sup> ions, 104  
N7-MTase domain, 103–104  
nsp10–nsp14 complexes, 104–105  
SARS-CoV, 102–103  
zinc finger, 105

N protein-mediated enhancement, 177–178

Nucleoprotein  
conservation of, 9, 9<sup>f</sup>  
C-terminal domain (CTD), 8–9  
kinases, 8  
N-terminal domain, 8–9

**P**

Pathogen recognition receptors (PRRs), 224–225

Protein kinase, RNA activated (PKR), 224–225

Protein suppressors, CoV  
7a protein, 180  
eIF3f, 180  
elongation factor 1 alpha (eEF1 $\alpha$ ), 180  
MERS-CoV nsp1, 179  
SARS-CoV nsp1, 179  
40S ribosomal subunits, 178–179

Proteolytic cleavage and conformational changes  
prefusion conformation, 40–41  
receptor mediated endocytosis, 39–40  
virus-cell fusion, 39–40

**R**

Receptor-binding domain (RBD), 37–38

Receptor interactions, S<sub>1</sub> subunit  
C-terminal region (CTR) changes, 43–44  
N-terminal region (NTR) changes, 42–43

Replication and transcription complex (RTC)  
IFN response, 221–222  
RNA synthesis and processing, 64, 112

Reverse genetics, FCoVs  
bacterial artificial chromosome (BAC), 207–208  
cDNA, 208–209  
FCoV Black sequence, 209–210  
recombinant viruses, 207  
targeted RNA recombination, 206–207

Ribosomal frameshift, 172–173

Ribosomal shunting mechanism, 174

RIG-I-like receptors (RLRs), 225

RNA-dependent RNA polymerase (RdRp)  
genome replication and transcription, 129–130  
inhibitors, 77–78

RNA-dependent RNA polymerase (RdRp)  
*(Continued)*  
 initiation mechanism, 74–77, 75*f*  
 recombinant expression, 74

RNA elements, CoV. *See cis*-acting RNA elements, CoV

RNA synthesis and processing, CoVs  
 accessory proteins, 64–65  
 antibody availability, 67  
 cell culture models, 66–67  
 3C-like protease (3CL<sup>pro</sup>), 61–63  
 core replicase domains, 61  
 error rate and genomic plasticity, 113  
 genome organization and expression strategy, 61–63, 62*f*  
 nidoviruses, 61  
 nsp 7, 67–68, 68*f*  
 nsp 9, 70–71  
 nsp 10, 71–72  
 nsp 10–13–14–16  
   cap structure, 91–92  
   interferon-stimulated genes (ISGs), 90–91  
   7-methylguanosine (<sup>m7</sup>G), 90  
 mRNA, 90–91  
 nsp14 N7-methyl transferase, 94–97, 95–96*f*  
 nsp16 2'-O-methyl transferase, 97–101, 99–100*f*  
 nsp13 RNA 5' triphosphatase, 92–93  
 RNA guanylyl transferase (GTase), 93

nsp12  
 characterization, 72–73  
 inhibitors, 77–78  
 initiation mechanism, 74–77, 75*f*  
 NiRAN domain, 78–80  
 RdRp domain, 73–74  
 virus-encoded RdRp, 72–73

nsp13  
 drug target, 89–90  
 functional characterization, nidovirus helicase, 86–89  
 HEL1, 81–83, 82*f*  
 helicase-associated ZBD, 83–84  
 nidovirus helicase structural biology, 84–86  
 superfamilies (SFs), 80–81

nsp15  
 conserved domain, 108  
 hexameric form, 109  
 hexamerization, 109  
 His residues, 110–111  
 interrelated by topological permutation, 109  
 Mn<sup>2+</sup> ions, 107–108  
 nidovirus endoU domains, 106–107, 107*f*  
 recombinant forms, 107–108  
 RNase A, 110  
 XendoU, *Xenopus laevis*, 106–107, 107*f*  
 nsp8 and nsp7–nsp8 complexes, 68–70  
 nsp 14 ExoN  
   DEDD exonucleases, 102  
   genome size and ExoN conservation, 102–103  
   metal ion-coordinating residues, 105–106  
   Mg<sup>2+</sup> or Mn<sup>2+</sup> ions, 104  
   N7-MTase domain, 103–104  
   nsp10–nsp14 complexes, 104–105  
   SARS-CoV, 102–103  
   zinc finger, 105  
 nsp interactome, 65–66  
 open reading frames (ORFs), 61–63  
 papain-like proteases (PL<sup>pro</sup>), 61–63  
 RTC, 64, 112  
 subgenomic (sg) mRNAs, 64–65  
 traditional genetic methods, 112–113  
 transcriptionregulatory sequences (TRSs), 65  
 transmission, 60–61  
 ubiquitin, 61–63

**S**

Severe acute respiratory syndrome (SARS) CoV  
 eEF $\alpha$ , 180  
 ER stress, 181  
 HCoV, 168  
 host mRNA decay, 184  
 IRES-driven translation, 179  
 nsp1, 179  
 stimulatory structure, 173

Spike protein  
 HR1 and HR2, 12–13  
 MERS-CoV, 12

S1 and S2 regions, 11–12  
SARS-CoV, 12  
Spike protein (S) and tropism changes, CoV  
cross-species transmission, 31  
MERS-CoV, 30–31  
mutations  
    FIPV, 41–42  
    S<sub>2</sub> mutations, altered tropism, 45–47  
    S<sub>1</sub> receptor interactions, 42–44  
origin, 30  
proteolytic cleavage and conformational changes  
prefusion conformation, 40–41  
receptor mediated endocytosis, 39–40  
virus-cell fusion, 39–40  
SARS-CoV, 30–31  
spike–receptor interactions  
    protein receptor preference, 39  
    RBD, 37–38  
structural proteins, 30  
structure of  
    S<sub>1</sub> subunit, 32–34, 33–36*f*  
    S<sub>2</sub> subunit, 33–34*f*, 34–37  
    trimers, 31–32  
Spike–receptor interactions  
    protein receptor preference, 39  
    RBD, 37–38  
S<sub>1</sub> subunit  
    RBD, 37–38  
    receptor interactions  
        C-terminal region (CTR) changes, 43–44  
        N-terminal region (NTR) changes, 42–43  
    structure of, 32–34, 33–36*f*  
S<sub>2</sub> subunit  
    mutations  
        altered tropism, 46–47  
        proteolytic cleavage sites, changes in, 45–46  
    structure of, 33–34*f*, 34–37  
Subunit vaccines, 254–256  
Supramolecular architecture  
    evolution, structural proteins  
        CTD, 15  
        M and N, 13–14  
    nidovirus structural proteins, 14–15, 14*f*  
pleomorphic nidovirus, 15–16  
VLP, 14–15  
packaged host-encoded protein, 1–2  
S–E–M–N genes, 2–4  
structure and organization, 2–4, 3*f*  
viral genome, 1–2  
viral proteins  
    envelope protein, 9–11  
    membrane protein, 5–8  
    nucleoprotein, 8–9  
    spike protein, 11–13  
virion structure and durability, 4–5

**T**

3'-terminal *cis*-acting RNA elements  
functional roles  
    BSL and pseudoknot, 146–147  
    hypervariable region (HVR), 147  
    3'-terminal poly(A) tail, 147–148  
structural features  
    bulged stem-loop (BSL), 143  
    hairpin-type pseudoknot (PK) structure, 143–144  
    hypervariable region (HVR), 145  
    MHV genome, 143–145  
TGEV and FCoV, 141–142

5'-terminal *cis*-acting RNA elements  
functional roles  
    DI RNA replication, 136–137  
    SARS-CoV, 136–137  
    stem-loop 3, 138–139  
    stem-loop 4, 139–140  
    stem-loop 5, 140–141  
    stem-loops 1 and 2, 137–138  
structural features  
    MHV, 133, 134*f*  
    RNA structure, 135–136  
    SARS-CoV, 133–135  
    selective 2'-hydroxyl acylation and primer extension (SHAPE) method, 135–136  
    stem-loops (SLs), 133  
Translation mechanism, CoV  
cap-dependent translation initiation, 167–168  
eukaryotic cells, 166–167

Translation mechanism, CoV (*Continued*)  
 eukaryotic initiation factors (eIFs), 167  
 internal ribosome entry site (IRES), 167–168

Transmissible gastroenteritis virus (TGEV), 195–196

Tropism changes, S protein mutations  
 canine CoVs (CCoVs), 41–42  
 feline CoV (FECV), 41–42  
 FIPV, 41–42  
 S<sub>2</sub> mutations  
   altered tropism, 46–47  
   proteolytic cleavage sites, changes in, 45–46

S<sub>1</sub> receptor interactions  
 C-terminal region (CTR) changes, 43–44  
 N-terminal region (NTR) changes, 42–43

Type I IFN system  
 induction of, 224–225  
 stimulated gene expression, 225–226  
 types and signaling pathways  
   IFN-gamma, 223  
   IFN-lambda 1–4, 223  
   ISG, 222

**U**  
 Upstream ORFs (uORF), 176

**V**  
 Vectored vaccines, 256–257  
 Viral and cellular mRNA translation, CoV.  
*See* mRNA translation, CoV  
 Viral enzymes, 171–172  
 Viral proteins, assembly and fusion  
   envelope protein  
 SARS-CoV, 10  
 structural features, 10–11  
 VLP, 9–10  
   membrane protein  
 appearance and characteristics, 7–8, 7*f*  
 endodomains, 6  
 MLONG–RNP interactions, 6  
 virus-like particles (VLP) assembly, 6–8

nucleoprotein  
 conservation of, 9, 9*f*  
 C-terminal domain (CTD), 8–9  
 kinases, 8  
 N-terminal domain, 8–9

spike protein  
 HR1 and HR2, 12–13  
 MERS-CoV, 12  
 S1 and S2 regions, 11–12  
 SARS-CoV, 12

Viral UTRs, 177

Virulence and vaccine development, CoV  
 ADEI and eosinophilia induction, 270–271  
 animal models  
   CRISPR–Cas9 system, 252–254  
   dipeptidyl peptidase-4 (DPP4), 252  
   HCoV-OC43, 251–252  
   hDPP4, 253  
   MERS-CoV, 252  
   SARS-CoV, 253

antigenic complexity, SARS- and MERS-CoV, 250–251

antiviral selection  
 enzymatic activities, 273  
 inhibitors, vacuolar acidification, 273–274  
 p38 MAPK, 274

B- and T-cell responses, requirement of, 249–250

dendritic cells (DCs)  
 cytokines and chemokines, 273  
 immune cells, SARS-CoV and  
   MERS-CoV, 271, 272*t*  
 MERS-CoV interaction, 272  
 SARS-CoV, 272–273  
 virus replication, 271–272

epithelial cells, 271

genome structure and protein composition, 248–249, 248*f*

human CoVs, 271

inactivated whole virus, 256

live-attenuated vaccines  
 engineer attenuated CoVs, 258  
 IFN sensitivity, 259–261  
 innate immunity modulators, 261–263, 261*f*

MERS-CoV genes, 267–269  
SARS-CoV genes, 263–267  
virulence of, 258–259  
macrophages (MØ)  
  cytokines and chemokines, 273  
  immune cells, SARS-CoV  
    and MERS-CoV, 271, 272*t*  
MERS-CoV interaction, 272

SARS-CoV, 272–273  
  virus replication, 271–272  
MERS-CoV, 247–248  
  pathogenesis, 246–247  
  prevalence, 246–247  
  SARS-CoV, 247–248  
  subunit vaccines, 254–256  
  vectored vaccines, 256–257